Gabelli Funds LLC Sells 30,100 Shares of Lantheus Holdings, Inc. $LNTH

Gabelli Funds LLC reduced its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 55.6% during the fourth quarter, Holdings Channel reports. The firm owned 24,000 shares of the medical equipment provider’s stock after selling 30,100 shares during the period. Gabelli Funds LLC’s holdings in Lantheus were worth $1,597,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Blue Trust Inc. raised its position in Lantheus by 30.3% in the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock worth $66,000 after acquiring an additional 230 shares during the period. United Community Bank raised its position in Lantheus by 15.6% in the third quarter. United Community Bank now owns 1,815 shares of the medical equipment provider’s stock worth $93,000 after acquiring an additional 245 shares during the period. Farther Finance Advisors LLC raised its position in Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 275 shares during the period. Verdence Capital Advisors LLC raised its position in Lantheus by 3.8% in the fourth quarter. Verdence Capital Advisors LLC now owns 8,455 shares of the medical equipment provider’s stock worth $563,000 after acquiring an additional 310 shares during the period. Finally, Concurrent Investment Advisors LLC raised its position in Lantheus by 10.3% in the third quarter. Concurrent Investment Advisors LLC now owns 3,936 shares of the medical equipment provider’s stock worth $202,000 after acquiring an additional 366 shares during the period. 99.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on LNTH shares. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Mizuho lifted their target price on shares of Lantheus from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. The Goldman Sachs Group restated a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Finally, JonesTrading lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $99.71.

Lantheus Price Performance

LNTH opened at $103.00 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. The stock has a market capitalization of $6.71 billion, a P/E ratio of 24.82 and a beta of -0.08. The company’s 50-day simple moving average is $83.62 and its two-hundred day simple moving average is $71.76. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $103.89.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. During the same quarter in the prior year, the business earned $1.53 EPS. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts predict that Lantheus Holdings, Inc. will post 4.41 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.